Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elian Keli
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Elian Keli is a Traditional Chinese Medicine (TCM) formulation primarily composed of extracts from *Curcuma zedoaria* (Ezhu) and *Coptis chinensis* (Huanglian). It is developed as a hospital-made preparation in China, specifically at the Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of TCM). The drug is primarily indicated for the treatment of chronic atrophic gastritis (CAG) and gastric precancerous lesions (GPL), including intestinal metaplasia and dysplasia. Elian Keli exerts its therapeutic effects by inhibiting the proliferation of gastric mucosal cells, inducing apoptosis, and suppressing inflammatory responses. Research indicates that it modulates key oncogenic signaling pathways, such as the PI3K/Akt and Wnt/beta-catenin pathways, to prevent or reverse the progression of gastric lesions toward malignancy.
- Brand names
- Elian Keli
- Other names
- Elian granulesEzhu-Huanglian granules莪连颗粒
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)CTNNB1 (Beta-catenin)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on Elian Keli.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elian Keli.